subject: Medical Stock Update From Pennytobuck On Genz, Pwrm, Enz [print this page] PWRM, Power 3 Medical Products IncPWRM, Power 3 Medical Products Inc. (PWRM.OB)
PWRM, a bio-technology company, engages in the development and marketing of diagnostic tests in the fields of cancer, and neurodegenerative and neuromuscular diseases in the United States. PWRMS products include BC-SeraPro, a proteomic blood serum test for the early detection of breast cancer; and NuroPro, a serum test for the detection of neurodegenerative diseases, such as amyotrophic lateral sclerosis, Alzheimers disease, and Parkinsons disease. PWRMs products analyze proteins and their mutations to assess an individuals risk for developing disease later in life or a patients likelihood of responding to a particular drug; assess a patients risk of disease progression and disease recurrence; and measure a patients exposure to drug therapy. PWRM was formerly known as Surgical Safety Products, Inc. and changed its name to Power3 Medical Products, Inc. in September 2003. PWRM was founded in 1992 and is based in The Woodlands, Texas.
To learn more about PWRM visit: http://www.Power3Medical.com
Enzo Biochem, Inc. (NYSE:ENZ) announced that its Enzo Clinical Labs division has been awarded a license for doing business in the Commonwealth of Pennsylvania, the first of several for which it has applied.
The Lab, headquartered in Farmingdale, NY, currently has pending license applications with the states of Maine, Maryland and California.
In recent years, our Company has invested heavily in the Clinical Lab, expanding our physical plant, adding advanced diagnostic equipment, and installing state of the art accounting systems and communications functionality, to speed accurate and prompt reports to our physician clients, said Barry Weiner, President of Enzo Biochem. Most notably, we have invested in top level professionals, attracting to the Lab highly regarded pathologists and experienced leaders in the diagnostics field.
Among the unique clinical diagnostic tests in development by ENZ are the ColonSentry colon cancer risk-stratification assay, multiplex DNA sequencing, alternative amplification/detection methods for pathogens, and cytogenetic tests for cancer using Enzo proprietary probe technology.
To learn more about ENZ visit: http://www.enzo.com
Genzyme Corporation (NASDAQ:GENZ) announced that the two-year follow-up results from the phase 2 clinical trial of its investigational therapy known as eliglustat tartrate have been accepted for publication in the journal Blood. The results have been pre-published on the journals website and are available to subscribers.
Eliglustat tartrate, a capsule taken orally, is being developed to provide a convenient treatment alternative for adult patients with Gaucher disease type 1, and to offer a broader range of treatment options for patients and physicians to achieve individual therapeutic goals. Current treatments, including GENZs Cerezyme (imiglucerase for injection), the standard of care for patients with Gaucher disease type 1, are administered through intravenous infusions.
GENZ reported last year that the 52-week phase 2 trial of eliglustat tartrate had met its primary composite endpoint: a clinically meaningful response in at least two of three endpoints (improvements in spleen size, hemoglobin and platelet levels) in individual patients. The two-year data to be published in Blood indicate continued improvements across all endpoints.
After two years, most patients (85%) had met at least three of the four hematologic and visceral therapeutic goals established for enzyme replacement therapy. These data also suggest that eliglustat tartrate may positively impact two indicators of bone disease, bone mineral density and the presence of dark marrow.
To learn more about GENZ visit http://www.genzyme.com/
For FREE Daily Stock Alerts & Updates Signup At: http://pennytobuck.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyToBuck.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer ( http://pennytobuck.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyToBuck.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations.The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB)
